Partners

Château Santé is a health technology company based in Zeist, the Netherlands, specializing in advanced electronic Patient-Reported Outcome Measures (ePROMs). Our mission is to improve health outcome measurement by focusing on what truly matters to patients.

Contribution to EuroHeartPath:
With our newly developed Cardio ePROM, we aim to quantify the overall impact of cardiac health complaints on patients' lives in clinical studies.

Cordys Analytics specializes in AI-driven ECG diagnostics for early detection of heart disease. Building on research from UMC Utrecht, Cordys has developed a vendor-neutral, cloud-based platform that integrates seamlessly into existing clinical workflows.

Contribution to EuroHeartPath:
Developing AI-driven ECG diagnostics for early detection and personalized treatment of heart disease, and enhancing remote monitoring using wearable technology.

The German Heart Centre Munich is one of the best-known centres for heart diseases in Germany and Europe. In the Department of Cardiovascular Diseases (Cardiology) you will find specialists for the treatment of circulatory disorders of the heart and the major arteries, specialists for the treatment of cardiac rhythm disorders and heart valve diseases as well as specialists for the treatment of cardiac muscle weakness and high blood pressure.

Contribution to EuroHeartPath:
To evaluate existing cardiovascular care pathways using robust data collection and analysis methodologies, and to develop protocols for systematic evaluation across EU countries.

The European Pathway Association is an international not for profit organisation of Clinical Pathway/ Care Pathway networks, user groups, academic institutions, supporting organisations and individuals who want to support the development, implementation and evaluation of clinical / care pathways.

Contribution to EuroHeartPath:
E-P-A is proud to be part of the EuroHeartPath consortium. Our specific contribution involves supporting the development of model pathways, and developing, delivering and evaluating care pathway training package, ultimately aiming to enhance cardiovascular healthcare delivery and outcomes.

The ESC is a volunteer-led, not-for-profit medical society, which brings together healthcare professionals from more than 150 countries, working to advance cardiovascular medicine and help people to live longer, healthier lives. Their mission is to reduce the burden of cardiovascular disease. The goal of the ESC is to facilitate the transfer of the new treatment into medical practice and to produce policy recommendations for policymakers and institutions.

Contribution to EuroHeartPath:
In EuroHeartPath, ESC is mostly involved as a WP partner, except for the WP9 Communication & Dissemination where ESC is the WP leader. • In WP2 ESC is involved by leveraging previous editions of the ESC Atlasand Burden of Disease knowledge by contributing to thorough qualitative and quantitative evaluations of existing care pathways in 15 EU countries. • In WP3, the ESC will support the identification and model of care pathways. • In WP4, it will provide additional insights extracted from one GRASP program study. • InWP6, ESC will contribute to the development of policy recommendations • In WP8, supporting the analysis of stakeholder and market needs while developing sustainable models. • ESC is leading WP9, focusing on the communication and dissemination of the project to ensure its impact and visibility.

IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and accelerate innovations. With approximately 88,000 employees in over 100 countries, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.

Contribution to EuroHeartPath:
IQVIA offers advanced data collection methods using CTcue technology for efficient and automated data acquisition from electronic health records. This will enable development of Digital Care Pathway mapping.

LSE is a unique institution dedicated to the field of social sciences. LSE academics continue to be the leading thinkers in this field, which includes the study and development of health policy and economics.

Contribution to EuroHeartPath:
LSE will investigate the health economic and policy aspects associated with the clinical interventions being investigated in EuroHeartPath. LSE academics will provide research that aims to pave the way for citizens and patients to access beneficial technologies.

Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more.

Contribution to EuroHeartPath:
Medtronic Integrated Health Solutions (IHS) is collaborating with the German Heart Center Charité (DHZC) in Berlin on one of the pioneering pathfinder studies. This partnership combines the expertise of a high-performance TAVI center with advanced knowledge in hospital Lean Six Sigma methods, focusing e.g. on enhanced digital engagement for patients and their families. By defining the ideal process steps to enhance recovery and improve patient outcomes, the collaboration aims to create an excellence pathway for TAVI treatment.

Medtronic is a global leader in medical technology, operating in over 150 countries with more than 95,000 employees. Its mission is to alleviate pain, restore health, and extend life. The company offers innovative solutions across over 70 medical conditions, particularly in cardiology, neurology, diabetes, and minimally invasive surgery.

Contribution to EuroHeartPath:
Medtronic Ibérica contributes to the project by bringing its expertise in the area of aortic stenosis. It will play an active role in mapping current processes and redesigning them to enable more effective and efficient patient diagnosis and treatment, increasing accessibility and reducing variability.

Outcomes'10' is a Spanish scientific and strategic consultancy specializing in Health Economics and Outcomes Research (HEOR), Market Access, and Real-World Evidence (RWE). Its multidisciplinary team includes professionals from various fields such as medicine, biology, biotechnology, pharmacy, mathematics, and statistics. The company offers end-to-end services, covering from project conception to results dissemination, with special focus on quality of work and customer care, becoming a flexible and reliable partner.

Contribution to EuroHeartPath:
Outcomes’10’s contribution to the study is primarily centered on Pathfinder 7, with a particular focus on regulatory procedures, the preparation of study documentation, cost analysis and interpretation of study outcomes.

Philips Cardiologs develops software solutions that utilize clinically validated artificial intelligence to facilitate ECG analysis. We are coordinating the WEAR study and, in collaboration with the ICPS and the APHP, we are seeking to evaluate AI-assisted triage and reporting for Holter recordings, with the aim of improving the efficiency of ambulatory cardiac monitoring.

Clinical Research in Cardiology

Contribution to EuroHeartPath:
Clinical Project Manager in Clinical Research at RCF@ICPS in Hospital Jacques Cartier, MASSY, France Collaboration with PHILIPS France in WARE Project. Inclusion patients in Clinical Study WARE

As the public body for health care in the Madrid Autonomous Region, SERMAS is an umbrella for different hospitals, health research institutes and primary & secondary care centres that assists millions of people 24/7. La Paz UH is the flagship of the organisation, serving as the referral hospital for around 750,000 inhabitants.

Contribution to EuroHeartPath:
In EuroHeartPath SERMAS will act as co-leader of WP7, with Medtronic, focused on scaling up and the optimisation of clinical workflows. We will also participate actively in the ASPIRE pilot study to implement digital solutions for optimising treatment pathways for people with aortic stenosis.

University Medical Center

Contribution to EuroHeartPath:

• co-PI in the GOLDEN-study
• GOLDEN Business Development / Project Management / Legal & Financial Matters

Van Vliet Diagnostics is part of Van Vliet Healthcare, a full-service provider of medical solutions. Van Vliet Healthcare offers a comprehensive range of products and services to the medical sector, including diagnostic equipment, medical consumables, and maintenance services for both equipment and medical facilities. Van Vliet Diagnostics specializes in point-of-care diagnostic devices and ultrasound systems. Through close collaboration with trusted manufacturers, we offer practical and reliable technologies that support the daily operations of hospitals, clinics, and other healthcare providers. Our goal is to contribute to efficient diagnostic workflows and consistent care quality. We place a strong emphasis on service, reliability, and practical support, helping healthcare facilities maintain high standards of hygiene, safety, and operational efficiency.

Contribution to EuroHeartPath:
Van Vliet Diagnostics is a contributor to Work Package 4 (DETECT) of the study, which focuses on the implementation of point-of-care testing (POCT) devices. Within this Work Package, three sub-studies are being conducted on the use of POCT, for which Van Vliet Diagnostics will supply two types of analyzers. As part of this collaboration, Van Vliet Diagnostics will not only provide the analyzers used in these studies, but will also support physicians in qualitatively evaluating their experiences with point-of-care testing (POCT). The important focus areas will be the feasibility, ease of use, and the impact of POCT on clinical practice, and this support be carried out throughout the entire duration of the project.

Viduet is a telemonitoring platform that allows patients to measure their health from home, with real-time data shared directly with healthcare providers. This helps improve early symptom detection, reduce unnecessary visits, and support better patient outcomes.

Contribution to EuroHeartPath:
Our contribution to the project is the collection of patient health data through Viduet's telemonitoring platform. This data will be securely gathered from patients remotely and used to support research aimed at improving healthcare.